Imaging biomarkers (IBs) are integral to the routine management of patients with cancer. IBs
used daily in oncology include clinical TNM stage, objective response and left ventricular …

The chemistry, radiochemistry, radiobiology, and radiopharmacology of radiopharmaceuticals
containing copper radionuclides are reviewed. Copper radionuclides offer application in …

Advances in the biomedical sciences have been accelerated by the introduction of many new
imaging technologies in recent years. With animal models widely used in the basic and pre…

Purpose: Locoregional tumor control for locally advanced cancers with radiation therapy
has been unsatisfactory. This is in part associated with the phenomenon of tumor hypoxia. …

89 Zr (half-life, 78.41 h) is a positron-emitting radionuclide that displays excellent potential
for use in the design and synthesis of radioimmunoconjugates for immunoPET. In the current …

Zirconium-89 is an attractive metallo-radionuclide for use in immuno-PET due to favorable
decay characteristics. Standardized methods for the routine production and isolation of high-…

The advent of antibody-based cancer therapeutics has led to the concomitant rise in the
development of companion diagnostics for these therapies, particularly nuclear imaging agents. …

MISO in vitro into EMT6 cells was investigated at the dissolved oxygen concentrations of 0, 1
x to3, 5 x 103, 5 x 10" and 2 x 105 ppm. Biodistribution performed at 1, 5, 10, 20 and 40 min …

Tumor hypoxia is recognized as an important determinant of response to therapy. In this
study we investigated the feasibility of clinical imaging with copper-60 diacetyl-bis(N 4 -…

PURPOSE: Tumor hypoxia is associated with poor response to therapy. We have investigated
whether pretreatment tumor hypoxia assessed by positron emission tomography (PET) …